A multicenter, randomized, double-blind, vehicle-controlled clinical study was conducted to evaluate the efficacy and safety of MAS063DP in 60 paediatric patients affected by atopic dermatitis (AD), aged between 2 and 17 years. Using the Investigator's Global Assessment (IGA) score for AD, patients with a score of 2 (mild) or 3 (moderate) were enrolled in the study. Patients were randomly selected to receive MAS063DP (20 patients), MAS060 (20 patients, a similar formulation with lower key ingredients' concentration and no preservatives) or vehicle (20 patients).The study consisted in a treatment period of 43 days, with clinical evaluations at baseline (day 1), days 8, 15, 22, 29 and 43, at which time the treatment was stopped. MAS063DP showed nearly 80% improvement in IGA score at day 22, compared with 16.6% and 26.3% with the MAS060 and vehicle respectively. A statistically significant difference was found by comparing MAS063DP with MAS060 (p < 0.0001); a similar result was evidenced comparing MAS063DP and vehicle (p = 0.001). By contrast, no significant difference was found between MAS060 and vehicle. A statistically significant difference was sustained until the end of the study. MAS063DP may therefore be considered as one of the available regimens effective in the treatment of mild-to-moderate AD in children and adolescents.

A. Patrizi, B. Capitanio, I. Neri, f. Giacomini, J.L. Sinagra, B. Raone, et al. (2008). A double-blind randomized vehicle-controlled clinical study to evaluate the efficacy and safety of MAS063Dp (Atopiclair TM) in the management of atopic dermatitis in paediatric patients. PEDIATRIC ALLERGY AND IMMUNOLOGY, 19(7), 619-625 [10.1111/j.1399-3038.2008.00724.x].

A double-blind randomized vehicle-controlled clinical study to evaluate the efficacy and safety of MAS063Dp (Atopiclair TM) in the management of atopic dermatitis in paediatric patients.

PATRIZI, ANNALISA;NERI, IRIA;GIACOMINI, FEDERICA;RAONE, BEATRICE;
2008

Abstract

A multicenter, randomized, double-blind, vehicle-controlled clinical study was conducted to evaluate the efficacy and safety of MAS063DP in 60 paediatric patients affected by atopic dermatitis (AD), aged between 2 and 17 years. Using the Investigator's Global Assessment (IGA) score for AD, patients with a score of 2 (mild) or 3 (moderate) were enrolled in the study. Patients were randomly selected to receive MAS063DP (20 patients), MAS060 (20 patients, a similar formulation with lower key ingredients' concentration and no preservatives) or vehicle (20 patients).The study consisted in a treatment period of 43 days, with clinical evaluations at baseline (day 1), days 8, 15, 22, 29 and 43, at which time the treatment was stopped. MAS063DP showed nearly 80% improvement in IGA score at day 22, compared with 16.6% and 26.3% with the MAS060 and vehicle respectively. A statistically significant difference was found by comparing MAS063DP with MAS060 (p < 0.0001); a similar result was evidenced comparing MAS063DP and vehicle (p = 0.001). By contrast, no significant difference was found between MAS060 and vehicle. A statistically significant difference was sustained until the end of the study. MAS063DP may therefore be considered as one of the available regimens effective in the treatment of mild-to-moderate AD in children and adolescents.
2008
A. Patrizi, B. Capitanio, I. Neri, f. Giacomini, J.L. Sinagra, B. Raone, et al. (2008). A double-blind randomized vehicle-controlled clinical study to evaluate the efficacy and safety of MAS063Dp (Atopiclair TM) in the management of atopic dermatitis in paediatric patients. PEDIATRIC ALLERGY AND IMMUNOLOGY, 19(7), 619-625 [10.1111/j.1399-3038.2008.00724.x].
A. Patrizi; B. Capitanio; I. Neri; f. Giacomini; J.L. Sinagra; B. Raone; E. Berardesca
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/57785
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 42
  • ???jsp.display-item.citation.isi??? 35
social impact